# EDGAR Filing Document

**Accession Number:** 0001970544
**File Stem:** 0001213900-26-003898
**Filing Date:** 2026-1
**Character Count:** 5700
**Document Hash:** 2961a77b063d1547ddc392e09199e64c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-003898.hdr.sgml**: 20260113

**ACCESSION NUMBER**: 0001213900-26-003898

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260113

**FILED AS OF DATE**: 20260113

**DATE AS OF CHANGE**: 20260113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pheton Holdings Ltd
- **CENTRAL INDEX KEY:** 0001970544
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42263
- **FILM NUMBER:** 26530048

**BUSINESS ADDRESS:**
- **STREET 1:** ROOM 306, NET BUILDING
- **STREET 2:** HONGJUNYING SOUTH RD, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 100012
- **BUSINESS PHONE:** 010-84817665

**MAIL ADDRESS:**
- **STREET 1:** ROOM 306, NET BUILDING
- **STREET 2:** HONGJUNYING SOUTH RD, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 100012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2026**

**Commission File Number: 001-42263**

**Pheton Holdings Ltd**

**Room 306, NET Building**

**Hong Jun Ying South Road, Chaoyang District**

**Beijing, China**

**(Address of Principal Executive Office)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release](ea027257001ex99-1_pheton.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Pheton Holdings Ltd** | **Pheton Holdings Ltd** |
| Date: January 13, 2026 | By: | /s/ Jianfei Zhang |
|  | Name: | Jianfei Zhang |
|  | Title: | Chief Executive Officer and Chairman of the Board of Directors |

---

## Exhibit 99.1

**Exhibit 99.1**

**Pheton Holdings Ltd Announces Corporate Name Change and Stock Ticker Symbol Change**

BEIJING, China, Jan. 13, 2026 (GLOBE NEWSWIRE) – Pheton Holdings Ltd (the "Company" or "Pheton"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, announced today that it will change its corporate name to iTonic Holdings Ltd, and change its stock ticker symbol to "ITOC" (collectively, the "Corporate Events"). The Company anticipates that the Corporate Events will be effective upon the commencement of trading on the Nasdaq Capital Market on January 16, 2026 (U.S. Eastern Time), at which time the Company's Class A ordinary shares will cease trading under the current ticker symbol "PTHL" and will begin trading under the new ticker symbol "ITOC" on the Nasdaq Capital Market. The corporate name change and stock ticker symbol change reflects the Company's new business strategy and its future development plans.

**About Pheton Holdings Ltd**

Founded in 1998, Pheton Holdings Ltd, through its wholly owned operating subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd., focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its lead product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Pheton Holdings is committed to leveraging its products and services to establish a potential new standard of care across multiple malignant tumor applications. For more information, please visit: http://www.ftzy.com.cn/ir.

**Safe Harbor Statement**

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, including but not limited to statements related to Pheton's cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. These forward-looking statements can be identified by terminology such as "aim," "anticipate," "believe," "estimate," "expect," "hope," "going forward," "intend," "ought to," "plan," "project," "potential," "seek," "may," "might," "can," "could," "will," "would," "shall," "should," "is likely to" and the negative form of these words and other similar expressions. Among other things, statements that are not historical facts, including statements about the Company's beliefs and expectations are or contain forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. All information provided in this press release is as of the date of this press release and is based on assumptions that the Company believes to be reasonable as of this date, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

**For investor and media inquiries, please contact:**

Pheton Holdings Ltd

Investor Relations

Email: ir@ftzy.com.cn

Lambert by LLYC

Jackson Lin

Phone: +1-646-717-4593

Email: jian.lin@llyc.global